Full Press Release Details
DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit, to take place October 12-14 in New York City and the Regional Biotechnology Conference, to take place October 15 in Doylestown, PA.
Maxim Growth Summit
| Date and Time: | Wednesday, October 14, 9am ET |
| Format: | Fireside Chat |
| Location: | Hard Rock Hotel, New York City |
A webcast of the fireside chat will be available on demand to registered conference attendees. For more information and a complete agenda, please refer to https://www.maximgrp.com/2026-growth-summit.
If you would like to arrange a 1on1 meeting with Aprea management during the conference, please contact your Maxim representative.
Regional Biotechnology Conference 2026
| Date and Time: | Thursday, October 15, 9am – 12noon ET |
| Format: | Panel Discussions |
| Location: | Pennsylvania Biotechnology Center |
| 3805 Old Easton Road, Doylestown, PA 18902 | |
For more information and a complete agenda, please refer to https://pabiocenter.org/pabc-calendar/.
About Aprea Therapeutics
Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.